Skip to main content
Erschienen in:

01.10.2014 | CME Zertifizierte Fortbildung

Therapie der indolenten Non-Hodgkin-Lymphome

verfasst von: Dr. T. Seiler, K. Herfarth, W. Klapper, M. Dreyling

Erschienen in: Die Onkologie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ziel

Dieser Artikel gibt einen Überblick über aktuelle Therapiestrategien bei indolenten Lymphomen.

Inhalte

Antikörperbasierte Therapieschemata sind bei vielen hämatologischen und onkologischen Erkrankungen als Therapiestandards etabliert und revolutionierten v. a. die Behandlung maligner Lymphome. 1997 wurde mit Rituximab der erste Antikörper von der US-amerikanischen Zulassungsbehörde zur Krebstherapie zugelassen. Sein Zielmolekül ist CD20, ein v. a. auf B-Lymphozyten und somit auf den meisten von B-Zellen abstammenden Non-Hodgkin-Lymphomen exprimiertes Protein. Vielversprechende Weiterentwicklungen des Antikörpers stehen in teils fortgeschrittenen Stadien der klinischen Prüfung. Tyrosinkinaseinhibitoren des B-Zell-Rezeptor-Signalpfads und immunmodulatorisch wirksame Substanzen sind weitere neue Therapiestrategien.

Schlussfolgerungen/Empfehlungen

Die Anti-CD20-basierte Therapie ist Standard bei vielen indolenten Lymphomen. Zielgerichtete und molekulare Therapieoptionen werden möglicherweise eine chemotherapiefreie Behandlung der indolenten Lymphome ermöglichen.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. WHO, Genf Swerdlow SH, Campo E, Harris NL (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. WHO, Genf
2.
Zurück zum Zitat Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol 29(14):1827–1834PubMedCrossRef Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol 29(14):1827–1834PubMedCrossRef
3.
Zurück zum Zitat Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169PubMedCrossRef Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169PubMedCrossRef
4.
Zurück zum Zitat Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504–1508PubMedCrossRef Buske C, Hoster E, Dreyling M et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504–1508PubMedCrossRef
5.
Zurück zum Zitat Herfarth K (2012) Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)). Blood 2012:1634 Herfarth K (2012) Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)). Blood 2012:1634
6.
Zurück zum Zitat Friedberg JW,Taylor MD, Cerhan JR et al (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202–1208PubMedCrossRefPubMedCentral Friedberg JW,Taylor MD, Cerhan JR et al (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202–1208PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516–522PubMedCrossRef Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516–522PubMedCrossRef
8.
Zurück zum Zitat Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725–3732PubMedCrossRef Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725–3732PubMedCrossRef
9.
Zurück zum Zitat Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986–1992PubMedCrossRef Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986–1992PubMedCrossRef
10.
Zurück zum Zitat Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586PubMedCrossRef Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586PubMedCrossRef
11.
Zurück zum Zitat Salles G, Mounier N, de Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13):4824–4831PubMedCrossRef Salles G, Mounier N, de Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13):4824–4831PubMedCrossRef
12.
Zurück zum Zitat Forstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064–3071PubMedCrossRef Forstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064–3071PubMedCrossRef
13.
Zurück zum Zitat Schulz H, Bohlius J, Skoetz N et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714PubMedCrossRef Schulz H, Bohlius J, Skoetz N et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714PubMedCrossRef
14.
Zurück zum Zitat Rummel MJ, Niederle M, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210PubMedCrossRef Rummel MJ, Niederle M, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210PubMedCrossRef
15.
Zurück zum Zitat Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51PubMedCrossRef Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51PubMedCrossRef
16.
Zurück zum Zitat Taverna CJ, Martinelli G, Hitz F et al (2013) Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized phase III trial SAKK 35/03. Blood 122:508 Taverna CJ, Martinelli G, Hitz F et al (2013) Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized phase III trial SAKK 35/03. Blood 122:508
17.
Zurück zum Zitat Hiddemann W, Dreyling M, Metzner B et al (2013) Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial immuno-chemotherapy (R-CHOP) or chemotherapy alone: analysis of 940 patients treated in prospective randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 122:419 Hiddemann W, Dreyling M, Metzner B et al (2013) Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial immuno-chemotherapy (R-CHOP) or chemotherapy alone: analysis of 940 patients treated in prospective randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 122:419
18.
Zurück zum Zitat Oers MH van, Glabbeke M van, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853–2858PubMedCrossRefPubMedCentral Oers MH van, Glabbeke M van, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853–2858PubMedCrossRefPubMedCentral
19.
Zurück zum Zitat Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003–4008PubMedCrossRef Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003–4008PubMedCrossRef
20.
Zurück zum Zitat Sebban C, Brice P, Delarue R et al (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620PubMedCrossRef Sebban C, Brice P, Delarue R et al (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620PubMedCrossRef
21.
Zurück zum Zitat Montoto S, Corradini P, Dreyling M et al (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 98(7):1014–1021PubMedCrossRefPubMedCentral Montoto S, Corradini P, Dreyling M et al (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 98(7):1014–1021PubMedCrossRefPubMedCentral
22.
Zurück zum Zitat Morel P, Duhamel A, Gobbi P et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170PubMedCrossRef Morel P, Duhamel A, Gobbi P et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170PubMedCrossRef
23.
Zurück zum Zitat Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al (2007) Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349PubMedCrossRef Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al (2007) Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349PubMedCrossRef
24.
Zurück zum Zitat Koch P, Probst A, Berldel WE et al (2005) Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23(28):7050–7059PubMedCrossRef Koch P, Probst A, Berldel WE et al (2005) Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23(28):7050–7059PubMedCrossRef
25.
Zurück zum Zitat Ahmed S, Kussick SJ, Siddiqui AK et al (2004) Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer 40(9):1320–1326PubMedCrossRef Ahmed S, Kussick SJ, Siddiqui AK et al (2004) Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer 40(9):1320–1326PubMedCrossRef
26.
Zurück zum Zitat Fasola CE, Jones JC, Huang DD et al (2013) Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 86(5):930–935PubMedCrossRef Fasola CE, Jones JC, Huang DD et al (2013) Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 86(5):930–935PubMedCrossRef
27.
Zurück zum Zitat Hoster E et al (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. ASH Annual Meeting Abstracts 114(22):880 Hoster E et al (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. ASH Annual Meeting Abstracts 114(22):880
28.
Zurück zum Zitat Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367(6):520–531PubMedCrossRef Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367(6):520–531PubMedCrossRef
29.
Zurück zum Zitat Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822–3829PubMedCrossRef Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822–3829PubMedCrossRef
30.
Zurück zum Zitat Zinzani PL, Vose JM, Czuczman MS et al (2013) Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 24(11):2892–2897PubMedCrossRefPubMedCentral Zinzani PL, Vose JM, Czuczman MS et al (2013) Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 24(11):2892–2897PubMedCrossRefPubMedCentral
31.
Zurück zum Zitat Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–516PubMedCrossRef Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–516PubMedCrossRef
Metadaten
Titel
Therapie der indolenten Non-Hodgkin-Lymphome
verfasst von
Dr. T. Seiler
K. Herfarth
W. Klapper
M. Dreyling
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 10/2014
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-014-2786-z

Weitere Artikel der Ausgabe 10/2014

Der Onkologe 10/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.